Corcept Therapeutics Inc. (CORT) is a publicly traded Healthcare sector company. As of May 21, 2026, CORT trades at $59.39 with a market cap of $5.92B and a P/E ratio of 58.52. CORT moved +1.58% today. Year to date, CORT is +68.98%; over the trailing twelve months it is -22.51%. Its 52-week range spans $28.66 to $117.33. Analyst consensus is strong buy with an average price target of $86.25. Rallies surfaces CORT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Corcept climbs as DAZALS two-year ALS survival data revives pipeline momentum: Corcept Therapeutics shares rose after the company disclosed new two-year overall survival data from its Phase 2 DAZALS study of dazucorilant in ALS. The update highlighted an 87% reduction in risk of death versus placebo in certain comparisons and reinforced plans to start a pivotal Phase 3 study later in 2026.
| Metric | Value |
|---|---|
| Price | $59.39 |
| Market Cap | $5.92B |
| P/E Ratio | 58.52 |
| EPS | $1.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $117.33 |
| 52-Week Low | $28.66 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $741.17M |
| Net Income | $106.11M |
| Gross Margin | 98.19% |
6 analysts cover CORT: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $86.25.